NCT07816835RecruitingPhase 4
Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
Multi-site, randomized controlled trial to determine whether patients who report NO symptomatic benefit with their maintenance hand-held inhaler(s), benefit upon switching to nebulized therapy using comparable classes of medications.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 8 Sept 2026
- Start date
- 14 Jul 2026
- Primary completion date
- Jun 2027
- Lead sponsor
- COPD Foundation
- Diseases
- COPD
- NCT number
- NCT07816835
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- From 14 Jul 2026 to the primary completion date, Jun 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current diagnosis of other respiratory disease including asthma, treatment with a LABA/LAMA slow mist inhaler or treatment with SABA/SAMA nebulizer medications 3-4 times per day as maintenance therapy
Other illness
- Current diagnosis of dementia or known cognitive impairment.
- Current impairment in manual dexterity (i.e., severe rheumatoid arthritis, severe tremor, etc)
Other
- Exacerbation of COPD within the last 2 months
- Current use of daily Prednisone as treatment for COPD
Who the study is looking for
- \> 10 pack-years smoking cigarettes
- Diagnosis of COPD based on GOLD Criteria
- Patients are clinically stable for the past 4 weeks
- Prior Pulmonary function tests showing FEV1 \< 50% predicted (either 30 minutes post albuterol or within 2-4 hours after using their maintenance long-acting inhaler) within the past 12 months.
- Currently using a single pMDI or a single DPI with either LABA/LAMA or LABA/LAMA/ICS therapy for at least one month.
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Midwest Chest Consultants, P.C. Coordinator of this site? Confirm its status | Saint Charles | United States | Recruiting |
| Southeastern Research Center Coordinator of this site? Confirm its status | Winston-Salem | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.